Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars announced.

On Wednesday, Biocon stock slipped 0.55 per cent to settle at Rs 364.55 apiece on the BSE.

Biocon has completed the acquisition of the remaining equity shares of its unlisted subsidiary Biocon Biologics from Mylan ...

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

Stocks to watch today: The stocks to watch today, 22 January 2026, include Eternal, InterGlobe Aviation, Eternal, Dr Reddy’s Laboratories, Biocon, Hindustan Petroleum Corporation Ltd (HPCL), CESC, ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key markets as it races to be among the first few to reap a windfall after patents on ...

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process.

Biocon Ltd on Monday said its wholly owned subsidiary, Biocon Pharma Ltd, has received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for ...

Biocon Ltd is quoting at Rs 383.95, up 1.31% on the day as on 12:49 IST on the NSE. The stock is down 2.48% in last one year as compared to a 11% jump in NIFTY and a 1.13% jump in the Nifty Pharma ...

(RTTNews) - Biocon Biologics Ltd (BBL), a unit of Biocon Ltd (BIOCON), Thursday said that the U.S. Food and Drug Administration (FDA) has approved Jobevne, a biosimilar to Bevacizumab. Bevacizumab, ...

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...